Are the hydrocodone and chlorpheniramine in Tussionex (hydrocodone bitartrate and chlorpheniramine maleate) only contained within the white sustained-release beads?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tussionex Formulation Composition

No, the hydrocodone and chlorpheniramine are not exclusively contained in white beads—Tussionex is formulated as an extended-release suspension where both active ingredients are distributed throughout the liquid vehicle, not isolated in discrete beads.

Understanding Tussionex Formulation

The question appears to stem from confusion about sustained-release delivery systems. While some extended-release medications use bead technology (such as certain methylphenidate formulations that contain medication particles in capsules 1), Tussionex operates differently.

Key Formulation Characteristics

  • Tussionex is a liquid suspension, not a capsule or tablet containing beads 2
  • The hydrocodone bitartrate and chlorpheniramine maleate are formulated together in a sustained-release delivery system designed to provide 12-hour duration of action 3
  • Both active ingredients are present throughout the suspension vehicle, allowing for gradual release over the dosing interval 3

Clinical Implications

Dosing Considerations

  • The sustained-release formulation provides more uniform plasma drug profiles compared to immediate-release products, with fewer occasions of super- or subtherapeutic concentrations 4
  • This delivery system is designed to maintain therapeutic levels of both the antitussive (hydrocodone) and antihistamine (chlorpheniramine) components throughout the 12-hour dosing interval 3

Important Safety Note

  • Tussionex is contraindicated in patients under 18 years of age due to unfavorable benefit-risk profile, with no robust efficacy data supporting pediatric use and significant safety concerns including respiratory depression 3
  • The formulation should never be divided, crushed, or altered, as this would destroy the sustained-release properties and could lead to rapid release of potentially fatal doses of hydrocodone 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.